The approach outlined here has provided an effective means of improving allograft survival, with 6-month survivals of 90% or better for every type of living-related transplant, i.e., HLA-identical siblings, nonidentical recipients with low MLCs, and nonidentical recipients with high MLCs given DSTs. Our center has confirmed the basic findings originally presented by the San Fransisco transplantation team. To those findings can now be added data to suggest that certain pairs of mismatched DR antigens are associated with either high or low MLC activity, specifically, DR3-DR6, DR4-DR Blank, and DR6-DR7 in the former group, and DR4-DR7 and DR6-DR Blank in the latter.
|Original language||English (US)|
|Number of pages||7|
|Journal||Cleveland Clinic Quarterly|
|State||Published - Dec 1 1982|
ASJC Scopus subject areas